| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Cytotoxic | 38 | 2019 | 501 | 5.950 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 39 | 2024 | 1199 | 5.300 |
Why?
|
| Virus Diseases | 21 | 2024 | 279 | 5.060 |
Why?
|
| T-Lymphocytes | 42 | 2025 | 1697 | 4.880 |
Why?
|
| Adoptive Transfer | 14 | 2020 | 237 | 2.600 |
Why?
|
| Immunotherapy, Adoptive | 31 | 2025 | 823 | 2.480 |
Why?
|
| Antigens, Neoplasm | 19 | 2024 | 382 | 2.280 |
Why?
|
| Adenoviridae | 22 | 2023 | 604 | 2.000 |
Why?
|
| Epstein-Barr Virus Infections | 12 | 2023 | 291 | 1.900 |
Why?
|
| Immunity, Cellular | 6 | 2023 | 202 | 1.710 |
Why?
|
| Herpesvirus 4, Human | 28 | 2023 | 671 | 1.680 |
Why?
|
| Adenoviridae Infections | 7 | 2013 | 70 | 1.680 |
Why?
|
| Immunotherapy | 13 | 2024 | 662 | 1.540 |
Why?
|
| CD8-Positive T-Lymphocytes | 14 | 2024 | 393 | 1.350 |
Why?
|
| Epitopes, T-Lymphocyte | 12 | 2020 | 126 | 1.310 |
Why?
|
| Immunocompromised Host | 9 | 2024 | 295 | 1.260 |
Why?
|
| Antigens, Viral | 14 | 2020 | 437 | 1.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2024 | 475 | 1.220 |
Why?
|
| Transplantation, Homologous | 16 | 2024 | 662 | 1.190 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 538 | 1.100 |
Why?
|
| Lymphocyte Transfusion | 3 | 2021 | 57 | 1.020 |
Why?
|
| Antigen-Presenting Cells | 10 | 2014 | 117 | 0.980 |
Why?
|
| Viruses | 2 | 2018 | 123 | 0.970 |
Why?
|
| Hematologic Neoplasms | 5 | 2015 | 286 | 0.970 |
Why?
|
| Graft vs Host Disease | 11 | 2024 | 543 | 0.970 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2021 | 30 | 0.950 |
Why?
|
| Cell- and Tissue-Based Therapy | 9 | 2024 | 159 | 0.930 |
Why?
|
| Receptors, Antigen, T-Cell | 10 | 2024 | 481 | 0.920 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2020 | 327 | 0.900 |
Why?
|
| Lymphocyte Activation | 15 | 2019 | 688 | 0.890 |
Why?
|
| Dendritic Cells | 11 | 2017 | 408 | 0.860 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 77 | 0.850 |
Why?
|
| Cytomegalovirus | 13 | 2019 | 270 | 0.840 |
Why?
|
| Salvage Therapy | 2 | 2021 | 194 | 0.810 |
Why?
|
| Lymphoma | 7 | 2021 | 322 | 0.740 |
Why?
|
| Humans | 106 | 2025 | 124398 | 0.700 |
Why?
|
| Viral Matrix Proteins | 12 | 2018 | 109 | 0.700 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 138 | 0.700 |
Why?
|
| Adenovirus Infections, Human | 3 | 2010 | 50 | 0.680 |
Why?
|
| Tumor Microenvironment | 5 | 2024 | 548 | 0.670 |
Why?
|
| T-Cell Antigen Receptor Specificity | 7 | 2021 | 58 | 0.640 |
Why?
|
| Cytotoxicity, Immunologic | 11 | 2025 | 262 | 0.630 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 171 | 0.610 |
Why?
|
| Epitopes | 5 | 2018 | 432 | 0.580 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 12 | 0.570 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 19 | 0.570 |
Why?
|
| DNA Viruses | 2 | 2017 | 33 | 0.570 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 47 | 0.560 |
Why?
|
| Metapneumovirus | 1 | 2017 | 51 | 0.560 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2014 | 22 | 0.540 |
Why?
|
| Herpesviridae Infections | 2 | 2018 | 142 | 0.530 |
Why?
|
| Graft Survival | 1 | 2018 | 528 | 0.510 |
Why?
|
| Neoplasms | 6 | 2022 | 2801 | 0.510 |
Why?
|
| Cytomegalovirus Infections | 4 | 2013 | 218 | 0.490 |
Why?
|
| Capsid Proteins | 2 | 2007 | 182 | 0.490 |
Why?
|
| Transplant Recipients | 3 | 2024 | 214 | 0.480 |
Why?
|
| Graft Rejection | 1 | 2018 | 588 | 0.470 |
Why?
|
| Cell Culture Techniques | 8 | 2019 | 288 | 0.460 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 8 | 0.460 |
Why?
|
| Cells, Cultured | 10 | 2012 | 3050 | 0.450 |
Why?
|
| Herpesvirus 6, Human | 2 | 2017 | 58 | 0.430 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 213 | 0.420 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 33 | 0.400 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2017 | 767 | 0.400 |
Why?
|
| Monocytes | 3 | 2012 | 352 | 0.400 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 685 | 0.400 |
Why?
|
| Virus Activation | 1 | 2012 | 87 | 0.390 |
Why?
|
| Genetic Therapy | 7 | 2024 | 683 | 0.390 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2014 | 196 | 0.390 |
Why?
|
| Immunophenotyping | 9 | 2019 | 329 | 0.390 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 446 | 0.370 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 4 | 2018 | 60 | 0.370 |
Why?
|
| Cell Line, Tumor | 17 | 2025 | 3341 | 0.360 |
Why?
|
| Tissue Donors | 5 | 2021 | 486 | 0.360 |
Why?
|
| Interleukin-12 | 2 | 2008 | 114 | 0.360 |
Why?
|
| Genetic Vectors | 8 | 2014 | 940 | 0.350 |
Why?
|
| Hodgkin Disease | 5 | 2014 | 293 | 0.340 |
Why?
|
| BK Virus | 3 | 2023 | 59 | 0.340 |
Why?
|
| Antigen Presentation | 6 | 2024 | 103 | 0.330 |
Why?
|
| Liver Transplantation | 1 | 2018 | 1039 | 0.330 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2023 | 47 | 0.320 |
Why?
|
| Adolescent | 16 | 2021 | 19358 | 0.320 |
Why?
|
| DNA, Viral | 2 | 2009 | 479 | 0.320 |
Why?
|
| Genetic Engineering | 3 | 2019 | 162 | 0.320 |
Why?
|
| Child, Preschool | 13 | 2023 | 14085 | 0.320 |
Why?
|
| Stem Cell Transplantation | 2 | 2009 | 238 | 0.300 |
Why?
|
| Adult | 20 | 2024 | 29396 | 0.300 |
Why?
|
| Allografts | 2 | 2021 | 190 | 0.290 |
Why?
|
| Male | 28 | 2024 | 61025 | 0.290 |
Why?
|
| Transgenes | 3 | 2014 | 337 | 0.290 |
Why?
|
| Interferon-gamma | 6 | 2020 | 502 | 0.280 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 669 | 0.280 |
Why?
|
| Child | 18 | 2023 | 24528 | 0.280 |
Why?
|
| Female | 27 | 2024 | 66305 | 0.280 |
Why?
|
| Coculture Techniques | 5 | 2019 | 233 | 0.270 |
Why?
|
| Cross Reactions | 2 | 2004 | 193 | 0.270 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2014 | 224 | 0.270 |
Why?
|
| Leukemia, Myeloid | 2 | 2020 | 85 | 0.270 |
Why?
|
| Young Adult | 7 | 2021 | 8979 | 0.260 |
Why?
|
| Lymphocyte Depletion | 4 | 2012 | 124 | 0.260 |
Why?
|
| Recurrence | 7 | 2022 | 1423 | 0.260 |
Why?
|
| Immune System Diseases | 1 | 2006 | 46 | 0.260 |
Why?
|
| Cell Communication | 1 | 2007 | 167 | 0.260 |
Why?
|
| Cell Proliferation | 10 | 2019 | 2304 | 0.250 |
Why?
|
| Leukemia | 3 | 2022 | 376 | 0.250 |
Why?
|
| Immunologic Memory | 5 | 2019 | 185 | 0.250 |
Why?
|
| Immunodominant Epitopes | 2 | 2017 | 50 | 0.240 |
Why?
|
| Transduction, Genetic | 7 | 2014 | 290 | 0.240 |
Why?
|
| Th1 Cells | 3 | 2020 | 154 | 0.240 |
Why?
|
| Flow Cytometry | 6 | 2012 | 802 | 0.240 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 2508 | 0.240 |
Why?
|
| Immunological Synapses | 1 | 2025 | 26 | 0.240 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 59 | 0.230 |
Why?
|
| Fetal Blood | 3 | 2010 | 176 | 0.230 |
Why?
|
| Middle Aged | 13 | 2024 | 26459 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 104 | 0.230 |
Why?
|
| Infant | 8 | 2023 | 12481 | 0.230 |
Why?
|
| DNA Virus Infections | 2 | 2017 | 22 | 0.220 |
Why?
|
| Cell Line | 8 | 2013 | 2770 | 0.220 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 72 | 0.210 |
Why?
|
| Fas Ligand Protein | 1 | 2022 | 33 | 0.210 |
Why?
|
| Peptides | 7 | 2024 | 793 | 0.210 |
Why?
|
| Vaccination | 3 | 2023 | 953 | 0.200 |
Why?
|
| Amino Acid Sequence | 6 | 2020 | 2699 | 0.200 |
Why?
|
| Killer Cells, Natural | 2 | 2022 | 324 | 0.200 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 645 | 0.200 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 226 | 0.200 |
Why?
|
| Virus Latency | 2 | 2002 | 61 | 0.200 |
Why?
|
| Feasibility Studies | 5 | 2017 | 767 | 0.190 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 11 | 0.190 |
Why?
|
| HEK293 Cells | 5 | 2018 | 753 | 0.190 |
Why?
|
| Antiviral Agents | 5 | 2023 | 746 | 0.190 |
Why?
|
| Animals | 19 | 2021 | 34139 | 0.190 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 47 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 887 | 0.180 |
Why?
|
| Prognosis | 5 | 2021 | 4554 | 0.180 |
Why?
|
| Interleukin-4 | 2 | 2018 | 139 | 0.180 |
Why?
|
| Transplantation Immunology | 2 | 2012 | 53 | 0.180 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 203 | 0.180 |
Why?
|
| Single-Chain Antibodies | 2 | 2011 | 43 | 0.180 |
Why?
|
| Smallpox | 1 | 2020 | 10 | 0.170 |
Why?
|
| Cyclin A1 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Monitoring, Immunologic | 1 | 2020 | 17 | 0.170 |
Why?
|
| Anemia | 1 | 2024 | 341 | 0.170 |
Why?
|
| Smallpox Vaccine | 1 | 2020 | 36 | 0.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 341 | 0.160 |
Why?
|
| Cytokines | 4 | 2019 | 1279 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1245 | 0.160 |
Why?
|
| Viral Load | 2 | 2018 | 384 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1127 | 0.160 |
Why?
|
| Blood Platelets | 2 | 2019 | 325 | 0.150 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 25 | 0.150 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 1149 | 0.150 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2009 | 51 | 0.150 |
Why?
|
| Virus Replication | 2 | 2020 | 609 | 0.150 |
Why?
|
| Interleukin-7 | 2 | 2009 | 44 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1240 | 0.150 |
Why?
|
| Membrane Glycoproteins | 2 | 2013 | 412 | 0.150 |
Why?
|
| Herpesviridae | 1 | 2018 | 31 | 0.140 |
Why?
|
| Granzymes | 1 | 2017 | 37 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2024 | 12287 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2023 | 6089 | 0.140 |
Why?
|
| Elephants | 1 | 2018 | 40 | 0.140 |
Why?
|
| Mice, SCID | 3 | 2014 | 571 | 0.140 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 66 | 0.140 |
Why?
|
| Viremia | 1 | 2018 | 128 | 0.140 |
Why?
|
| Peptide Fragments | 5 | 2013 | 749 | 0.140 |
Why?
|
| HLA Antigens | 4 | 2012 | 242 | 0.140 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 38 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 998 | 0.140 |
Why?
|
| Mucin-1 | 2 | 2013 | 35 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 810 | 0.140 |
Why?
|
| Adenoviruses, Human | 3 | 2017 | 81 | 0.130 |
Why?
|
| Viral Proteins | 1 | 2018 | 348 | 0.130 |
Why?
|
| Epitope Mapping | 3 | 2013 | 78 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 459 | 0.120 |
Why?
|
| Gene Expression | 4 | 2017 | 1569 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1404 | 0.120 |
Why?
|
| Conserved Sequence | 2 | 2007 | 293 | 0.120 |
Why?
|
| Myeloablative Agonists | 1 | 2015 | 25 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 56 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 212 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2013 | 816 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 672 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 260 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 1531 | 0.110 |
Why?
|
| Receptors, LDL | 1 | 2014 | 89 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 205 | 0.110 |
Why?
|
| Caspase 9 | 1 | 2014 | 75 | 0.110 |
Why?
|
| Cell Engineering | 1 | 2013 | 21 | 0.110 |
Why?
|
| Gene Transfer Techniques | 3 | 2010 | 357 | 0.110 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2014 | 84 | 0.110 |
Why?
|
| Mutation | 2 | 2024 | 5809 | 0.110 |
Why?
|
| Peptide Library | 2 | 2011 | 56 | 0.110 |
Why?
|
| Species Specificity | 1 | 2014 | 548 | 0.110 |
Why?
|
| Blood Donors | 2 | 2011 | 62 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5107 | 0.110 |
Why?
|
| Flutamide | 1 | 2013 | 26 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 19 | 0.100 |
Why?
|
| Histocompatibility Testing | 2 | 2013 | 148 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 323 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 188 | 0.100 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2013 | 28 | 0.100 |
Why?
|
| Aged | 6 | 2024 | 19479 | 0.100 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 57 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 204 | 0.100 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 48 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 174 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2018 | 3068 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2012 | 1245 | 0.100 |
Why?
|
| CD28 Antigens | 2 | 2025 | 78 | 0.100 |
Why?
|
| Mice | 9 | 2021 | 17725 | 0.100 |
Why?
|
| Risk Factors | 2 | 2018 | 10149 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 89 | 0.100 |
Why?
|
| CD40 Ligand | 1 | 2012 | 64 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2017 | 520 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 578 | 0.100 |
Why?
|
| HLA-A Antigens | 3 | 2011 | 35 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 2 | 2011 | 300 | 0.090 |
Why?
|
| Azacitidine | 1 | 2011 | 54 | 0.090 |
Why?
|
| Receptors, Antigen | 1 | 2011 | 34 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2005 | 3873 | 0.090 |
Why?
|
| Tumor Escape | 2 | 2013 | 61 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 256 | 0.090 |
Why?
|
| Chills | 1 | 2010 | 6 | 0.090 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 6 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 37 | 0.090 |
Why?
|
| Oncolytic Virotherapy | 1 | 2012 | 84 | 0.090 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2014 | 57 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 14 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 22 | 0.090 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 12 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 969 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 366 | 0.090 |
Why?
|
| Leukemia, B-Cell | 1 | 2010 | 26 | 0.080 |
Why?
|
| Antigens | 1 | 2010 | 156 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 108 | 0.080 |
Why?
|
| Plasmids | 1 | 2010 | 514 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2011 | 153 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2009 | 84 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2010 | 107 | 0.080 |
Why?
|
| Stem Cells | 1 | 2014 | 701 | 0.080 |
Why?
|
| Retinoblastoma | 1 | 2010 | 110 | 0.080 |
Why?
|
| Interleukins | 1 | 2009 | 120 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2013 | 1064 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2012 | 334 | 0.070 |
Why?
|
| Fever | 1 | 2010 | 296 | 0.070 |
Why?
|
| Cell Line, Transformed | 3 | 2014 | 169 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2013 | 820 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 515 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2019 | 1930 | 0.070 |
Why?
|
| Cell Survival | 2 | 2019 | 806 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1899 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2007 | 170 | 0.070 |
Why?
|
| Virion | 2 | 2020 | 148 | 0.060 |
Why?
|
| K562 Cells | 3 | 2011 | 95 | 0.060 |
Why?
|
| Cell Separation | 3 | 2012 | 229 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2007 | 145 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 722 | 0.060 |
Why?
|
| Biomarkers | 2 | 2019 | 2980 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 543 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2023 | 406 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.060 |
Why?
|
| Cell Transformation, Viral | 1 | 2005 | 106 | 0.060 |
Why?
|
| GPI-Linked Proteins | 2 | 2018 | 98 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 421 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4355 | 0.060 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 27 | 0.060 |
Why?
|
| Albumins | 1 | 2024 | 89 | 0.060 |
Why?
|
| Feces | 1 | 2007 | 717 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 124 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1584 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 27 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Phosphoproteins | 3 | 2012 | 404 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 1684 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 282 | 0.050 |
Why?
|
| Homeostasis | 1 | 2007 | 692 | 0.050 |
Why?
|
| HLA-A2 Antigen | 2 | 2013 | 25 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 421 | 0.050 |
Why?
|
| Vaccinia virus | 1 | 2020 | 52 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Antigens, CD19 | 2 | 2011 | 176 | 0.040 |
Why?
|
| Alleles | 1 | 2004 | 1614 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2025 | 4534 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 301 | 0.040 |
Why?
|
| Phenotype | 2 | 2024 | 4255 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2011 | 862 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 107 | 0.040 |
Why?
|
| Time Factors | 3 | 2014 | 6272 | 0.040 |
Why?
|
| Gene Editing | 1 | 2019 | 193 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 426 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 173 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 1288 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 16 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2014 | 51 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 807 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 58 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 41 | 0.030 |
Why?
|
| Balloon Occlusion | 1 | 2014 | 47 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 103 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 40 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 64 | 0.030 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 46 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 68 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 45 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 274 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 109 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 19 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2013 | 18 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2014 | 493 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 85 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 520 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 128 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 749 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 118 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 383 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 525 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2012 | 54 | 0.020 |
Why?
|
| Muromonab-CD3 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 281 | 0.020 |
Why?
|
| Carcinoma | 1 | 2014 | 280 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1482 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 795 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 470 | 0.020 |
Why?
|
| Telomerase | 1 | 2012 | 160 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 772 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 111 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 152 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 285 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 36 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 163 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2010 | 95 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 440 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 13 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 298 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 49 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2010 | 60 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 117 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 150 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 76 | 0.020 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 237 | 0.020 |
Why?
|
| Lentivirus | 1 | 2009 | 83 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 548 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 183 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 353 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 288 | 0.020 |
Why?
|
| Eye | 1 | 2010 | 227 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2009 | 225 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2009 | 219 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2007 | 13 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 16 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 1069 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 1761 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 378 | 0.020 |
Why?
|
| Melanoma | 1 | 2014 | 832 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 675 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 617 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 352 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1228 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2007 | 376 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2005 | 56 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2005 | 202 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2824 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 2805 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1459 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2088 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 1264 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2004 | 179 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2873 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1085 | 0.010 |
Why?
|
| Apoptosis | 1 | 2009 | 1789 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3687 | 0.010 |
Why?
|
| Capsid | 1 | 2002 | 142 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 889 | 0.010 |
Why?
|
| United States | 1 | 2010 | 10773 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 8185 | 0.010 |
Why?
|